

Status: Currently Official on 16-Feb-2025  
Official Date: Official Prior to 2013  
Document Type: USP Monographs  
DocId: GUID-1D03EB25-EB24-47B7-8807-FF381E54E1BF\_1\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M68520\\_01\\_01](https://doi.org/10.31003/USPNF_M68520_01_01)  
DOI Ref: 3qro9

© 2025 USPC  
Do not distribute

# Prednicarbate Ointment

**DEFINITION**  
Prednicarbate Ointment contains NLT 90.0% and NMT 110.0% of the labeled amount of prednicarbate ( $C_{27}H_{36}O_8$ ) in a suitable ointment base.

**IDENTIFICATION**  
• **A.** The retention time of the prednicarbate peak in the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

**ASSAY**  
• **PROCEDURE**  
**Solution A:** 0.01 M monobasic potassium phosphate  
**Solution B:** Acetonitrile and dehydrated alcohol (2:1)  
**Mobile phase:** See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	67	33
5	67	33
45	40	60
50	40	60
55	20	80
70	20	80
75	67	33
85	67	33

**Standard stock solution:** 0.3 mg/mL [USP Prednicarbate RS](#) in dehydrated alcohol  
**Standard solution:** 30 µg/mL of [USP Prednicarbate RS](#) prepared as follows. Transfer 10.0 mL of the *Standard stock solution* to a 100-mL volumetric flask. Add 15 mL of tetrahydrofuran and 30 mL of *Solution B*, and dilute with *Solution A* to volume.  
**System suitability stock solution 1:** 0.3 mg/mL each of [USP Prednicarbate Related Compound B RS](#) and [USP Prednicarbate Related Compound C RS](#) in dehydrated alcohol  
**System suitability stock solution 2:** Transfer 15 mg of [USP Prednicarbate Related Compound A RS](#) to a 50-mL volumetric flask. Add 1.0 mL of *System suitability stock solution 1*, and dilute with dehydrated alcohol to volume.  
**System suitability solution:** Transfer 10.0 mL of the *Standard solution* to a volumetric flask. Add 1.0 mL of *System suitability stock solution 2*, 1 mL of tetrahydrofuran, and 2 mL of acetonitrile. Dilute with *Solution A* to 20.0 mL.  
**Sample solution:** Transfer the equivalent of 3.0 mg of prednicarbate from a quantity of Ointment to a 100-mL volumetric flask. Add 15 mL of tetrahydrofuran, shake vigorously, and allow to stand in an ultrasonic bath until the sample has dissolved. Add 20 mL of dehydrated alcohol, and shake vigorously. Add 20 mL of acetonitrile, and shake vigorously. Immediately dilute with *Solution A* to volume, and shake vigorously. Allow to stand in an ice bath for at least 15 min. Shake vigorously, and pass through a folded paper filter. Pass the filtrate through a membrane filter of 0.45-µm pore size.

**Chromatographic system**(See [Chromatography \(621\), System Suitability](#).)**Mode:** LC**Detector:** UV 243 nm**Column:** 4.0-mm × 25-cm; 5-μm packing L1**Column temperature:** 40°**Flow rate:** 1 mL/min**Injection volume:** 60 μL**System suitability****Samples:** *Standard solution* and *System suitability solution***Suitability requirements****Resolution:** NLT 1.5 between prednicarbate and prednicarbate related compound A, *System suitability solution***Tailing factor:** 0.7–1.5, *Standard solution***Relative standard deviation:** NMT 2.0%, *Standard solution***Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the percentage of the labeled amount of prednicarbate ( $C_{27}H_{36}O_8$ ) in the portion of Ointment taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 $r_U$  = peak response from the *Sample solution* $r_S$  = peak response from the *Standard solution* $C_S$  = concentration of [USP Prednicarbate RS](#) in the *Standard solution* (mg/mL) $C_U$  = nominal concentration of prednicarbate in the *Sample solution* (mg/mL)**Acceptance criteria:** 90.0%–110.0%**IMPURITIES****• ORGANIC IMPURITIES****Solution A, Solution B, System suitability stock solution 1, System suitability stock solution 2, Mobile phase, Standard stock solution, Standard solution, System suitability solution, Sample solution, and Chromatographic system:** Proceed as directed in the Assay.**Sensitivity solution:** 0.03 μg/mL of [USP Prednicarbate RS](#) prepared as follows. Dilute 1.0 mL of the *Standard solution* with dehydrated alcohol to 50.0 mL. Dilute 1.0 mL of the resulting solution with *Solution A* to 20.0 mL.**System suitability****Samples:** *Standard solution, System suitability solution, Sensitivity solution***Suitability requirements****Resolution:** NLT 1.5 between prednicarbate and prednicarbate related compound A, *System suitability solution***Tailing factor:** 0.7–1.5, *Standard solution***Relative standard deviation:** NMT 2.0%, *Standard solution***Signal-to-noise ratio:** NLT 3, *Sensitivity solution***Analysis****Sample:** *Sample solution*

Calculate the percentage of each related compound and unknown impurity in the portion of Ointment taken:

$$\text{Result} = (r_U/r_T) \times 100$$

 $r_U$  = peak response for each impurity $r_T$  = sum of all the peak responses**Acceptance criteria:** See [Table 2](#).**Table 2**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Prednicarbate related compound B	0.57	2.0
Prednicarbate related compound C	0.64	2.0
Prednicarbate	1.0	—
Prednicarbate related compound A	1.04	—
Any individual related compound	—	0.5
Total impurities	—	5.0

## PERFORMANCE TESTS

- **MINIMUM FILL:** Meets the requirements

## SPECIFIC TESTS

- **CONSISTENCY:** At room temperature, a string of Ointment having a length of 2 cm retains its shape on a glass plate for at least 10 min. It can be spread easily and has no visible lumps.
- **MICROBIAL ENUMERATION TESTS (61)** and **TESTS FOR SPECIFIED MICROORGANISMS (62):** It meets the requirements of the tests for the absence of *Staphylococcus aureus* and *Pseudomonas aeruginosa*. The total aerobic bacterial count does not exceed  $10^2$  cfu/g.

## ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers, and store at controlled room temperature.
- **USP REFERENCE STANDARDS (11).**  
[USP Prednicarbate RS](#)  
[USP Prednicarbate Related Compound A RS](#)  
1,2-Dihydroprednicarbate.  
[USP Prednicarbate Related Compound B RS](#)  
Prednisolone-17-ethylcarbonate.  
[USP Prednicarbate Related Compound C RS](#)  
Prednisolone-21-propionate.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
PREDNICARBATE OINTMENT	<a href="#">Documentary Standards Support</a>	SM52020 Small Molecules 5
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM52020 Small Molecules 5

**Chromatographic Database Information:** [Chromatographic Database](#)

## Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 32(3)

**Current DocID:** GUID-1D03EB25-EB24-47B7-8807-FF381E54E1BF\_1\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M68520\\_01\\_01](https://doi.org/10.31003/USPNF_M68520_01_01)

**DOI ref:** [3qro9](#)